Cargando…
Development of radiation countermeasure agents for acute radiation syndromes
The risk of internal and external exposure to ionizing radiation (IR) has increased alongside the development and implementation of nuclear technology. Therefore, serious security issues have emerged globally, and there has been an increase in the number of studies focusing on radiological preventio...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486342/ https://www.ncbi.nlm.nih.gov/pubmed/37642199 http://dx.doi.org/10.1002/ame2.12339 |
_version_ | 1785102984228634624 |
---|---|
author | Guan, Bowen Li, Deguan Meng, Aimin |
author_facet | Guan, Bowen Li, Deguan Meng, Aimin |
author_sort | Guan, Bowen |
collection | PubMed |
description | The risk of internal and external exposure to ionizing radiation (IR) has increased alongside the development and implementation of nuclear technology. Therefore, serious security issues have emerged globally, and there has been an increase in the number of studies focusing on radiological prevention and medical countermeasures. Radioprotective drugs are particularly important components of emergency medical preparedness strategies for the clinical management of IR‐induced injuries. However, a few drugs have been approved to date to treat such injuries, and the related mechanisms are not entirely understood. Thus, the aim of the present review was to provide a brief overview of the World Health Organization's updated list of essential medicines for 2023 for the proper management of national stockpiles and the treatment of radiological emergencies. This review also discusses the types of radiation‐induced health injuries and the related mechanisms, as well as the development of various radioprotective agents, including Chinese herbal medicines, for which significant survival benefits have been demonstrated in animal models of acute radiation syndrome. |
format | Online Article Text |
id | pubmed-10486342 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104863422023-09-09 Development of radiation countermeasure agents for acute radiation syndromes Guan, Bowen Li, Deguan Meng, Aimin Animal Model Exp Med Regular Articles The risk of internal and external exposure to ionizing radiation (IR) has increased alongside the development and implementation of nuclear technology. Therefore, serious security issues have emerged globally, and there has been an increase in the number of studies focusing on radiological prevention and medical countermeasures. Radioprotective drugs are particularly important components of emergency medical preparedness strategies for the clinical management of IR‐induced injuries. However, a few drugs have been approved to date to treat such injuries, and the related mechanisms are not entirely understood. Thus, the aim of the present review was to provide a brief overview of the World Health Organization's updated list of essential medicines for 2023 for the proper management of national stockpiles and the treatment of radiological emergencies. This review also discusses the types of radiation‐induced health injuries and the related mechanisms, as well as the development of various radioprotective agents, including Chinese herbal medicines, for which significant survival benefits have been demonstrated in animal models of acute radiation syndrome. John Wiley and Sons Inc. 2023-08-29 /pmc/articles/PMC10486342/ /pubmed/37642199 http://dx.doi.org/10.1002/ame2.12339 Text en © 2023 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Regular Articles Guan, Bowen Li, Deguan Meng, Aimin Development of radiation countermeasure agents for acute radiation syndromes |
title | Development of radiation countermeasure agents for acute radiation syndromes |
title_full | Development of radiation countermeasure agents for acute radiation syndromes |
title_fullStr | Development of radiation countermeasure agents for acute radiation syndromes |
title_full_unstemmed | Development of radiation countermeasure agents for acute radiation syndromes |
title_short | Development of radiation countermeasure agents for acute radiation syndromes |
title_sort | development of radiation countermeasure agents for acute radiation syndromes |
topic | Regular Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486342/ https://www.ncbi.nlm.nih.gov/pubmed/37642199 http://dx.doi.org/10.1002/ame2.12339 |
work_keys_str_mv | AT guanbowen developmentofradiationcountermeasureagentsforacuteradiationsyndromes AT lideguan developmentofradiationcountermeasureagentsforacuteradiationsyndromes AT mengaimin developmentofradiationcountermeasureagentsforacuteradiationsyndromes |